The reformulated rivoceranib and camrelizumab combination therapy shows 23.8-month overall survival, underscoring first-line 바카라 사이트 먹튀 competitiveness
[by Yu, Suin] HLB announced on November 27 that the final analysis of its global Phase 3 clinical trial (CARES-310) evaluating the combination therapy of rivoceranib and camrelizumab (hereinafter referred to as rivo+camrel), currently being developed as a first-line 바카라 사이트 먹튀 for unresectable hepatocellular carcinoma, has been published in The Lancet Oncology, one of the leading journals in the oncology field.
Following the initial publication of key CARES-310 findings in The Lancet in July 2023, the company noted that the release of the full clinical dataset, including a post-hoc analysis, in this highly prestigious journal further reinforces the clinical value of the rivo+camrel combination. The study reaffirmed a median overall survival (mOS) of 23.8 for the rivo+camrel regimen, underscoring its superior therapeutic efficacy compared to competing 바카라 사이트 먹튀s.
In the 2023 analysis, the median operating range (MOS) for the rivo+camrel combination was reported at 22.1 months, compared with 14.9 months for the sorafenib group. However, the final analysis, incorporating additional follow-up, confirmed an mOS of 23.8 months versus 15.2 months, reaffirming the survival advantage (HR 0.64, 95% CI 0.52–0.79). The objective response rate (ORR) for the rivo+camrel regiment also increased from 25% to 27% in the final analysis, representing a marked difference of 21%P (percentage points) compared with the 6% for sorafenib.
Notably, the paper includes new post-hoc analyses from CARES-310, further elucidating the long-term survival benefit and consistency of 바카라 사이트 먹튀 response for the combination therapy, thereby strengthening its clinical persuasiveness. In the landmark OS analysis, the rivo+camrel combination achieved OS rates of 77%, 49%, and 38% at 12, 24, and 36 months, respectively, demonstrating consistently superior long-term survival compared with the sorafenib group (61%, 33%, and 25%).
The median duration of response (mDOR) reached 17.5 months, indicating a more durable 바카라 사이트 먹튀 response than that observed in the sorafenib group (9.2 months). The time to response (TTR) for the rivo+camrel combination was 1.9 months, compared with the sorafenib group (3.7 months).
Moreover, subgroup analyses stratified by age, race, serum alpha-fetoprotein (AFP), Barcelona Clinic Liver Cancer (BCLC) stage, and macrovascular invasion (MVI) consistently yielded hazard ratios (HRs) below 1 across most patient cohorts, indicating that the 바카라 사이트 먹튀 effect was not confined to any specific population. HLB emphasized that these findings reinforce the stable competitiveness of the first-line 바카라 사이트 먹튀 across all auxiliary indicators, regardless of disease stage or prognostic factors.
"The publication of the final CARES-310 analysis results in The Lancet Oncology, one of the world's most prestigious academic journals, further strengthens the clinical value and scientific credibility of the rivo+camrel combination therapy. In particular, the consistent efficacy observed across multiple subgroup analyses, alongside the overall survival benefit, clearly underscores the competitiveness of this regimen as a first-line treatment for hepatocellular carcinoma," said Han Yong-hae, Chief Technology Officer (CTO) of HLB Group.